The best way to play the biotech boom

Syncona is an unusual investment trust that invests in promising privately held biotech companies. It should be a core holding in any portfolio, says David Stevenson.

Scientist working in a laboratory © iStockphotos

Syncona: buy while the entry price is right

Syncona is an unusual investment trust that invests in promising privately held biotech companies. It should be a core holding in any portfolio, says David Stevenson.

Investors in the biotech sector have had a tough time over the last year. High valuations and concern over regulators and politicians attempting to lower drug prices have hit the Nasdaq Biotech index, which contains 220 companies. This benchmark has fallen by 11.39% over the last 12 months, compared with a gain of 18.7% for the S&P 500 index.

The long-term growth story, however, remains compelling. An ageing society is demanding better, more targeted medicines and technology is rising to the occasion, as the genomics-led revolution in care shows. Big Pharma gets the story, which is why it's been buying into the sector for the last few years in order to replenish its portfolios.

The best way in

But listed businesses only represent a portion of the available biotech universe of businesses. Many of the most interesting firms are privately held, usually with venture-capital firms as investors. Few vehicles provide access to this sector.

In my view the core holding for biotech investors should be Syncona (LSE: SYNC). I've held shares in this fund for years and I recently topped up my holdings. I think it is by far the best way of accessing privately held biotech firms. Recent share-price weakness offers an excellent chance to get on board.

The Syncona story is unusual. It started out as an independent investment business trading within the Wellcome Trust. It then merged with a UK trust called BACIT (Battle against Cancer investment trust), which was running a multi-fund portfolio. The merged entity is in effect a world-leading life-sciences venture capitalist joined at the hip with a traditional multi-fund manager kicking off cash that can be reinvested in private businesses. Followers of the Warren Buffett approach to investing will spot a classic ploy use a cash float from a boring business to provide growth capital for equity investments.

A good eye for winners

Syncona passes this challenge easily. It's already produced two exits in its short listed life. Blue Earth Diagnostics, the prostate-cancer imaging company, was sold to Bracco Imaging in late June. The other was Nightstar Therapeutics, a Nasdaq-listed retinal gene-therapy company. Syncona made a tenfold and a 4.5-fold return on these two companies respectively. Since December 2016 Syncona's share price has risen by around 70%, while its net asset value (NAV) gained 38% in the year to April. After its recent deals, Syncona is flush with cash worth around £915m, or 70% of assets.

According to funds analysts at Numis, a stockbroker, this might act as a "drag on NAV growth in the near term, but leaves the business well-financed to support growth in its existing portfolio, as well as to support new initiatives".

We can certainly see that last point emerging at the portfolio level. Syncona has founded three new portfolio companies over the past year: OMass Therapeutics (drug discovery), Anaveon (immuno-oncology), and Quell Therapeutics (cell therapy).

A treatment for haemophilia

But not every business in its portfolio has had such good luck. One portfolio business called Autolus Therapeutics, which is a Nasdaq-listed company, has seen its share price fall 47% since April, driven lower in part by worries that co-investor Neil Woodford might sell stock to help with his own issues. It's not too difficult to see why investors might be wary. The portfolio has a young, risky feel to it. There's a mountain of cash that will need to be invested to make a return, probably at the rate of between £100m and £200m per annum. And investors have slightly soured on biotech firms more generally. As a result, Syncona's share price is down by 6.7% over the last six months. At approximately 245p a share, it is trading at roughly 20% above the NAV based on calculations from Numis. For a potential high-growth fund, that looks to me like a more than decent entry price.

Recommended

Three winners of the long-term biotech boom
Share tips

Three winners of the long-term biotech boom

Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…
22 Mar 2021
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Feb 2021
Where to find deep value in investment trusts
Share tips

Where to find deep value in investment trusts

Professional investors Nick Greenwood and Charlotte Cuthbertson of the Miton Global Opportunities trust pick three of their favourite investment trust…
15 Feb 2021
Why investment trusts are the connoisseur’s choice of fund
Investment trusts

Why investment trusts are the connoisseur’s choice of fund

Investment trusts have justified their reputation as the best type of collective investment in 2020, says Jonathan Davis.
7 Dec 2020

Most Popular

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021
Nuclear power might never be popular – but now looks a good time to invest
Commodities

Nuclear power might never be popular – but now looks a good time to invest

Nuclear power gets a very bad press, but it is the ultimate renewable energy source. Interest in it is perking up again, says John Stepek. Which means…
9 Apr 2021
House prices: from boom to even bigger boom
House prices

House prices: from boom to even bigger boom

UK house prices have risen to new to record highs, says Nicole Garcia Merida. Demand continues to outpace supply, but continued low interest rates, th…
9 Apr 2021